Stryker Co. (NYSE:SYK) Shares Bought by Brown Lisle Cummings Inc.

Brown Lisle Cummings Inc. raised its holdings in shares of Stryker Co. (NYSE:SYK) by 2.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 6,568 shares of the medical technology company’s stock after acquiring an additional 182 shares during the quarter. Brown Lisle Cummings Inc.’s holdings in Stryker were worth $2,365,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in the business. Calamos Wealth Management LLC boosted its holdings in shares of Stryker by 4.1% in the 4th quarter. Calamos Wealth Management LLC now owns 960 shares of the medical technology company’s stock valued at $346,000 after buying an additional 38 shares in the last quarter. Patron Partners LLC increased its position in shares of Stryker by 135.8% during the fourth quarter. Patron Partners LLC now owns 2,030 shares of the medical technology company’s stock worth $731,000 after purchasing an additional 1,169 shares in the last quarter. Columbus Macro LLC grew its stake in Stryker by 474.2% during the 4th quarter. Columbus Macro LLC now owns 14,494 shares of the medical technology company’s stock worth $5,219,000 after buying an additional 11,970 shares during the last quarter. Trust Point Inc. boosted its holdings in shares of Stryker by 7.7% in the fourth quarter. Trust Point Inc. now owns 1,885 shares of the medical technology company’s stock valued at $679,000 after acquiring an additional 134 shares during the period. Finally, Baltimore Washington Financial Advisors Inc. raised its position in Stryker by 2.1% in the 4th quarter. Baltimore Washington Financial Advisors Inc. now owns 68,103 shares of the medical technology company’s stock valued at $24,521,000 after purchasing an additional 1,422 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Trading Down 0.1 %

Shares of SYK opened at $390.97 on Tuesday. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The stock has a fifty day moving average of $376.68 and a two-hundred day moving average of $363.22. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The company has a market capitalization of $149.05 billion, a PE ratio of 50.38, a price-to-earnings-growth ratio of 2.78 and a beta of 0.96.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the prior year, the firm earned $3.46 EPS. As a group, analysts forecast that Stryker Co. will post 13.5 EPS for the current year.

Stryker Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Tuesday, December 31st were given a dividend of $0.84 per share. This is a positive change from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date of this dividend was Tuesday, December 31st. This represents a $3.36 annualized dividend and a yield of 0.86%. Stryker’s dividend payout ratio is 43.30%.

Insider Buying and Selling

In other news, CEO Kevin Lobo sold 57,313 shares of the firm’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the transaction, the chief executive officer now directly owns 100,027 shares in the company, valued at $36,879,954.90. This trade represents a 36.43 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

SYK has been the subject of a number of research reports. BTIG Research upped their target price on shares of Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. JMP Securities reaffirmed a “market perform” rating on shares of Stryker in a report on Tuesday, January 7th. Needham & Company LLC restated a “buy” rating and issued a $442.00 target price on shares of Stryker in a research note on Wednesday, January 29th. UBS Group boosted their price target on shares of Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Finally, Piper Sandler reiterated an “overweight” rating and set a $420.00 target price (up previously from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $419.37.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.